These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28763112)

  • 1. Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: An assessment of trial quality.
    Kistler KD; Xu Y; Zou KH; Ntanios F; Chapman DS; Luo X
    Neurourol Urodyn; 2018 Jan; 37(1):54-66. PubMed ID: 28763112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
    Vouri SM; Kebodeaux CD; Stranges PM; Teshome BF
    Arch Gerontol Geriatr; 2017; 69():77-96. PubMed ID: 27889591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
    Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
    Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H; Chen H; Zhang Y; Cui Y
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.
    Evans CNB; Badenhorst A; Van Wijk FJ
    BMC Womens Health; 2024 May; 24(1):290. PubMed ID: 38755593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrical stimulation with non-implanted electrodes for overactive bladder in adults.
    Stewart F; Gameiro OL; El Dib R; Gameiro MO; Kapoor A; Amaro JL
    Cochrane Database Syst Rev; 2016 Apr; 4():CD010098. PubMed ID: 27037009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current pharmacotherapy of overactive bladder.
    Kreydin EI; Gomes CM; Cruz F
    Int Braz J Urol; 2021; 47(6):1091-1107. PubMed ID: 34003613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future pharmacotherapy for treating overactive bladder.
    Thiagamoorthy G; Cardozo L; Robinson D
    Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome reporting in randomized controlled trials (RCTs) on the pharmacological management of idiopathic overactive bladder (OAB) in women; a systematic review for the development of core outcome sets (COS).
    Moussa R; Rada MP; Durnea C; Falconi G; Betschart C; Haddad JM; Sedgwick P; Doumouchtsis SK;
    Int Urogynecol J; 2022 May; 33(5):1243-1250. PubMed ID: 35006311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of female overactive bladder syndrome and treatment-related effects.
    Hsiao SM; Lin HH
    J Formos Med Assoc; 2018 Oct; 117(10):871-878. PubMed ID: 29398096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.